Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

AstraZeneca Pharma India Ltd. (ASTR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
5,347.20 -207.55    -3.74%
05:30:26 - Real-time Data. Currency in INR ( Disclaimer )
Type:  Equity
Market:  India
ISIN:  INE203A01020 
S/N:  ASTRAZEN
  • Volume: 60,994
  • Bid/Ask: 5,347.00 / 5,348.00
  • Day's Range: 5,346.45 - 5,547.95
AstraZeneca Pharma 5,347.20 -207.55 -3.74%

NS:ASTR Financials

 
A brief overview of the NS:ASTR financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of AstraZeneca Pharma over time.

AstraZeneca Pharma India Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 3,110.72 million compared to INR 2,361.27 million a year ago. Revenue was INR 3,194.45 million compared to INR 2,429.21 million a year ago. Net income was INR 523.7 million compared to INR 325.64 million a year ago. Basic earnings per share from continuing operations was INR 20.95 compared to INR 13.03 a year ago. Diluted earnings per share from continuing operations was INR 20.95 compared to INR 13.03 a year ago.For the six months, sales was INR 6,065.38 million compared to INR 4,684.57 million a year ago. Revenue was INR 6,230.15 million compared to INR 4,793.67 million a year ago. Net income was INR 1,062.31 million compared to INR 527.17 million a year ago. Basic earnings per share from continuing operations was INR 42.49 compared to INR 21.09 a year ago. Diluted earnings per share from continuing operations was INR 42.49 compared to INR 21.09 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ASTR Income Statement

Gross margin TTM 59.43%
Operating margin TTM 14.99%
Net Profit margin TTM 11.64%
Return on Investment TTM 21.35%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 3057.89 3110.72 2954.57 2847.03
Gross Profit 1574.98 1889.42 1848.71 1800.67
Operating Income 113.52 490.86 634.38 555.95
Net Income 158.01 523.7 538.61 172.69

ASTR Balance Sheet

Quick Ratio MRQ 1.49
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 0.82%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 11015.61 9848.7
Total Liabilities 4465.96 3961.8
Total Equity 6549.65 6549.65 5886.9 5886.88

ASTR Cash Flow Statement

Cash Flow/Share TTM 28.55
Revenue/Share TTM 478.81
Operating Cash Flow  -
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change in Cash
* In Millions of INR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ASTR Comments

Write your thoughts about AstraZeneca Pharma India Ltd.
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Prakash Nambisan
Prakash Nambisan May 17, 2021 4:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
since the trail of vaccine is paused, what is the future ??
Prakash Nambisan
Prakash Nambisan May 03, 2021 5:46AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is it going to fly or move slowly...
Prakash Nambisan
Prakash Nambisan May 03, 2021 5:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is it going to fly ? or move slowly...
Prakash Nambisan
Prakash Nambisan May 03, 2021 5:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
is it going to fly ? or move slowly...
Abhay Bhandari
Abhay Bhandari Feb 15, 2021 4:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what is future of this share
Shreya Dey
Shreya Dey Jan 21, 2021 10:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong Buy! there is still time to enter...
Shreya Dey
Shreya Dey Jan 21, 2021 10:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong Buy! there is still time to enter...
Sagar Lakhisarani
Sagar Lakhisarani Dec 30, 2020 3:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
AstraZeneca's stock to cross 6000 mark very soon
Sagar Lakhisarani
Sagar Lakhisarani Dec 30, 2020 3:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
AstraZeneca's stock to cross 6000 mark very soon
Sandeep Kumar
Sandeep Kumar Nov 23, 2020 6:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Interim data show the #OxfordVaccine ( Astrazeneca) is 70.4% effective, & tests on two dose regimens show that it could be 90%.Astrazeneca vaccine is Ideally best vaccine for developing & underdeveloped countries like India, Africa & many others whereas Vaccine from Pfizer & Moderna's which need extremely cold storage & supply chain Support maintaining Anywhere from -20° C to -70°C becomes making it less feasible compared to Astrazeneca which just requires Normal refrigeration temp.Additionally 2 shots giving efficacy of over 90% Is great.. Israel have already placed orders with Astrazeneca for 10 million vaccine & India is going to ask emergency use Authorization from WHO..
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email